Track topics on Twitter Track topics that are important to you
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...
Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.
Multiple sclerosis is a major cause of neurological disability, which accrues predominantly during progressive forms of the disease. Although development of multifocal inflammatory lesions is the unde...
In findings that show the effectiveness of a new strategy for treating multiple sclerosis (MS), researchers are reporting positive results from three large, international, multicenter Phase III clinic...
Cells in the immune system of patients with multiple sclerosis behave differently from those of healthy individuals. Researchers at Linköping University in Sweden have exploited this difference to de...
Inhibition of the protein kinase CK2 prevents the development of auto-aggressive T cells, say multiple sclerosis researchers. Multiple sclerosis is the most common chronic inflammatory disease of the ...
Roche announced today new analyses from the three OCREVUS® (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) will be presente...
Roche announced today new analyses from the three OCREVUS® (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) will be presented du...
Multiple sclerosis is an inflammatory and neurodegenerative, autoimmune CNS disorder that is—at least in the early phase—amenable to treatment with various immunomodulatory drugs.1 The approval of...
Ocrevus (ocrelizumab), developed by Genentech, a member of Roche Group, is indicated for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis.
Corrigendum to Ragheb, S et al. (2011). Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid Multiple Sclerosis Journal 17(07) 819-829. [DOI: 10.1177/1352458511398887].
The main objective of this survey of persons with multiple sclerosis was to describe their employment situation. Secondary objectives were to ascertain when and how multiple sclerosis symptoms first i...
It is well known that multiple sclerosis (MS) patients are very sensitive to heat events. However, how MS patients respond to the significant temperature difference between the high- and low-latitude ...
Previous studies have suggested a relationship between neuroanatomical and neurofunctional hippocampal alterations and episodic memory impairments in multiple sclerosis (MS) patients.
To investigate levels of oxysterols in healthy control (HC) and multiple sclerosis (MS) patients and their interdependence with demographic, clinical characteristics, and cholesterol biomarkers.